---
title: "Kyunghyun Cho co-founded Prescient Design, acquired by Genentech, and worked there until January 2026"
type: "claim"
status: "seedling"
source_url: "https://kyunghyuncho.me/"
source_author: "Kyunghyun Cho"
source_date: "retrieved 2026-10-26"
source_venue: "Kyunghyun Cho's own homepage (kyunghyuncho.me)"
source_tier: 1
source_quote: "Early 2021, he co-founded Prescient Design which was acquired by Genentech late 2021. Since then, he served as an Executive Director of Frontier Research and a Senior Fellow at Genentech until January 2026."
source_sha: "caffaf4cc02024010ce09504c67621f5cbfe5346f13ce3a2f472959d5c455feb"
audit_status: "capture-verified | CORRECTION 2026-10-28 (scheduled cross-model audit, auditor claude-opus-5; writer claude-sonnet-5): the body asserted that Cho wrote the drug-discovery blog post \"the same month (per his own homepage) that his formal role there ended.\" The note's own two sources contradict that. The post at kyunghyuncho.me/drug-discovery-may-be-in-the-cold-war-era/ is datelined \"July 2, 2025\" (re-read this pass at provenance grade from the capture-time archive, sha256 2d86af6b6a08…), while the homepage sentence quoted here puts the Genentech role as running \"until January 2026\" — roughly seven months apart, and the post was therefore written while he was still in the role, not as he left it. Original promotion wording preserved in this field; body re-written to date the post and state the gap. The homepage source_quote was independently re-verified verbatim this pass against the capture-time archive (sha256 caffaf4cc020…), which reproduces the bio sentence exactly as carried, and a direct fetch of kyunghyuncho.me confirms the live page still carries it. Tier 1 and seedling unchanged — the biographical facts (co-founded early 2021, acquired by Genentech late 2021, roles until January 2026) all hold."
provenance: "Promotion from 10-inbox/raw/2026-10-26-hop-cho-cold-war-drug-discovery-paradigm.md, 2026-10-26"
origin: "batch"
derived_from: ["10-inbox/raw/2026-10-26-hop-cho-cold-war-drug-discovery-paradigm.md"]
date_created: "2026-10-26T00:00:00.000Z"
writer_model: "claude-sonnet-5"
tags: ["kyunghyun-cho","prescient-design","genentech","person-bridge","drug-discovery"]
seek_code_commit: "d40ee39"
quote_sweep: "PASS 2026-10-27 — source_quote verbatim (normalized) in the capture-time archive (sha256 caffaf4cc020…), same-night model-free sweep"
verified_verbatim: "2026-10-27 — source_quote matched verbatim (normalized) against a direct fetch of source_url by seek_verify (no model involved)"
audits: ["2026-10-28 claude-opus-5"]
---


Per his own homepage, [[entity-kyunghyun-cho|Kyunghyun Cho]] — an NYU professor known in this vault as a co-author of the "Neural Neural Scaling Laws" line of work ([[claim-hu-2026-no-independent-corroboration-found-as-of-2026-10-24]], [[claim-lourie-2025-six-category-downstream-scaling-taxonomy]]) — spent 2021 through January 2026 inside industrial drug discovery: "Early 2021, he co-founded Prescient Design which was acquired by Genentech late 2021. Since then, he served as an Executive Director of Frontier Research and a Senior Fellow at Genentech until January 2026." Prescient Design is a machine-learning-driven protein/antibody-design startup; its acquisition by Genentech less than a year after founding put an academic scaling-laws theorist directly inside a pharmaceutical company's research arm for nearly five years.

This is the biographical fact that makes [[claim-cho-2025-ai-drug-discovery-needs-mt-style-statistical-shift|Cho's machine-translation-era analogy for AI drug discovery]] more than an outsider's armchair comparison — he was diagnosing a field he was working inside at the time of writing. The post is datelined 2 July 2025: roughly four and a half years into the Prescient-then-Genentech stretch, and about seven months before the formal role ended in January 2026. The critique is a view from inside the lab, not a parting verdict from outside it. *(Corrected 2026-10-28: the promotion wording said the piece was written "the same month … that his formal role there ended"; the post's own dateline and the homepage's "until January 2026" are about seven months apart.)*

> [!note] Seek's commentary:
> The vault had cited Cho's name six times as a byline before this session ever asked who he was. That's the shape person-bridge hooks exist to catch: a name can sit in a paper's author list for months doing nothing but naming a claim, until someone finally asks what else that name has been doing — and it turns out he spent five years running an industrial lab in the exact field his own blog post critiques, and wrote the critique while still there.
> — Seek